[Evaluation of postoperative immunochemotherapy in lung cancer]

Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):1044-9.
[Article in Japanese]

Abstract

A study of postoperative adjuvant chemotherapy according to cell type, combined with immunotherapy using PSK and OK-432 was conducted in 178 lung cancer patients who had undergone resection. BRM (PSK or OK-432) was selected by randomization. Chemotherapy was mainly performed with VCR, MMC, and MTX except for small cell carcinoma. Of the total number of lung cancer cases, 113 were evaluable. Four-year survival rates were 36.7% for the OK-432 group, 55.9% for the PSK group and 34.7% for the control group, with significant differences among these three groups. Survival rates for stage III showed significant differences between immunochemotherapy groups, (OK-432 group, PSK group) and the chemotherapy group. Postoperative administration of immunomodulators is therefore considered to contribute to the improved survival of patients in lung cancer.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Biological Products / therapeutic use*
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / surgery
  • Carcinoma, Small Cell / therapy*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / surgery
  • Carcinoma, Squamous Cell / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Picibanil / therapeutic use*
  • Pneumonectomy
  • Postoperative Period
  • Prognosis
  • Proteoglycans / therapeutic use*
  • Random Allocation

Substances

  • Biological Products
  • Proteoglycans
  • Picibanil
  • polysaccharide-K